DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Wednesday morning. The firm issued a hold rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Price Performance

Shares of NASDAQ DBVT opened at $4.45 on Wednesday. The company has a 50 day simple moving average of $4.11 and a 200-day simple moving average of $3.83. The company has a market capitalization of $91.53 million, a P/E ratio of -0.99 and a beta of 0.67. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.09.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.